Tetra Offers Pro-Bono Regulatory and Quality Assurance Expertise to Companies Developing COVID-19 Solutions
Tetra Bio-Pharma volunteers tto guide medical device/ health-related manufacturers
OTTAWA, April 8, 2020 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development has joined the battle to fight the novel COVID-19 virus. The Company will mobilize its expertise in regulatory affairs and quality assurance to support Canadian businesses seeking Health Canada approval for specific products used to mitigate the ongoing COVID-19 pandemic.
This week Tetra Bio-Pharma submitted a Drug Information Number (DIN) application to Health Canada on behalf of a Canadian company ready to produce a hospital, institutional grade hard surface disinfectant. Tetra provided its intellectual know-how on a pro-bono basis. These regulatory services would typically cost companies thousands of dollars using a third-party service provider. Equally important are the efficiencies and time savings realized, which could mean a faster delivery of goods that are in tremendous demand.
"COVID-19 is unprecedented in our lifetime and calls for an unprecedented response from all of us," says Tetra Bio-Pharma CEO and CRO, Dr. Guy Chamberland. “Our staff of more than 30 experts in the fields of medical devices and drugs have decades of experience and regulatory knowledge in preparing and filing applications to regulators like Health Canada and FDA. Tetra also enjoys numerous years of experience in Quality Assurance (QA) with a team experienced in international requirements for drugs and medical devices. Helping these entrepreneurs secure approvals and avoid unnecessary delays in doing so may help save lives, which is why we support these efforts at 100 percent. Needless to say, this goes beyond our normal daily routine, our top priorities remain the SERENITY©, PLENITUDE© and HCC-011 projects".
"We are committed to doing whatever we can to help flatten the curve of this life-threating virus." said Tetra's President Sylvain Chrétien. "The Tetra team is used to going above and beyond the call of duty and our QA and regulatory affairs colleagues have the ability to provide the kind of insights that could bring these vital products to the frontline faster. Tetra is pleased to be able to use its internal resources to provide these services without the Company incurring additional expenses.”